Skip to main content


BARDA partners with Merck and IAVI to accelerate development of a vaccine to prevent COVID-19

BARDA Response

BARDA will collaborate with Merck and IAVI to accelerate development of an rVSV-SARS-CoV2 (recombinant) COVID-19 vaccine.

By leveraging experience from the manufacturing process for the FDA-licensed Ebola vaccine, ERVEBO®, this partnership allows streamlined development of a COVID-19 vaccine. Based on experience with the rVSV-based Ebola vaccine, a COVID-19 vaccine using the same rVSV platform, has potential to provide a rapid and robust immune response that could provide protection against COVID-19 after a single dose.

Vaccination against COVID-19 will strengthen the nation’s ability to protect those at home and abroad from health security threats and to save lives. This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.

About Merck:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world.

About IAVI:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov